TherapeuticsMD Inc
TXMD1.100USD
-0.010-0.90%
Cierre 08/04, 16:00（ET）Cotizaciones retrasadas 15 min
12.73MCap. mercado
PérdidaP/E TTM
Más Datos de TherapeuticsMD Inc Compañía
TherapeuticsMD, Inc. is a pharmaceutical royalty company, which primarily collects royalties from its licensees. It receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. It granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).
Información de la empresa
Símbolo de cotizaciónTXMD
Nombre de la empresaTherapeuticsMD Inc
Fecha de salida a bolsaJan 31, 2001
Director ejecutivoMr. Marlan D. Walker, J.D.
Número de empleados1
Tipo de seguridadOrdinary Share
Fin del año fiscalJan 31
Dirección951 Yamato Road, Suite 220
CiudadBOCA RATON
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal33431
Teléfono15619611900
Sitio Webhttps://www.therapeuticsmd.com/
Símbolo de cotizaciónTXMD
Fecha de salida a bolsaJan 31, 2001
Director ejecutivoMr. Marlan D. Walker, J.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Marlan D. Walker, J.D.
Mr. Marlan D. Walker, J.D.
Chief Executive Officer
Chief Executive Officer
73.64K
+3.94%
Mr. Cooper C. Collins
Mr. Cooper C. Collins
Independent Director
Independent Director
60.52K
--
Dr. Gail K. Naughton, Ph.D.
Dr. Gail K. Naughton, Ph.D.
Independent Director
Independent Director
8.50K
--
Mr. Joseph Ziegler
Mr. Joseph Ziegler
Principal Financial Officer, Principal Accounting Officer
Principal Financial Officer, Principal Accounting Officer
7.50K
--
Mr. Justin Roberts
Mr. Justin Roberts
Independent Director
Independent Director
--
--
Gov. Thomas G. (Tommy) Thompson, J.D.
Gov. Thomas G. (Tommy) Thompson, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Marlan D. Walker, J.D.
Mr. Marlan D. Walker, J.D.
Chief Executive Officer
Chief Executive Officer
73.64K
+3.94%
Mr. Cooper C. Collins
Mr. Cooper C. Collins
Independent Director
Independent Director
60.52K
--
Dr. Gail K. Naughton, Ph.D.
Dr. Gail K. Naughton, Ph.D.
Independent Director
Independent Director
8.50K
--
Mr. Joseph Ziegler
Mr. Joseph Ziegler
Principal Financial Officer, Principal Accounting Officer
Principal Financial Officer, Principal Accounting Officer
7.50K
--
Mr. Justin Roberts
Mr. Justin Roberts
Independent Director
Independent Director
--
--
Gov. Thomas G. (Tommy) Thompson, J.D.
Gov. Thomas G. (Tommy) Thompson, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de jul
Divisa: USDActualizado: dom., 6 de jul
FY2025Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
Non-U.S
219.00K
55.73%
United States
174.00K
44.27%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 17 de may
Actualizado: sáb., 17 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Rubric Capital Management LP
25.46%
Clearline Capital LP
5.49%
The Vanguard Group, Inc.
3.30%
Tejara Capital Ltd.
2.98%
Adar1 Capital Management LLC
2.33%
Other
60.44%
Accionistas
Accionistas
Proporción
Rubric Capital Management LP
25.46%
Clearline Capital LP
5.49%
The Vanguard Group, Inc.
3.30%
Tejara Capital Ltd.
2.98%
Adar1 Capital Management LLC
2.33%
Other
60.44%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
33.68%
Investment Advisor
7.67%
Investment Advisor/Hedge Fund
1.60%
Individual Investor
1.55%
Research Firm
1.14%
Other
54.36%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
88
5.28M
45.65%
+1.46M
2025Q1
93
3.58M
30.94%
-393.28K
2024Q4
95
3.73M
32.32%
-2.03M
2024Q3
99
3.59M
31.15%
-463.34K
2024Q2
121
3.62M
31.37%
-2.25M
2024Q1
209
3.66M
32.13%
-802.21K
2023Q4
230
4.54M
44.12%
-1.60M
2023Q3
274
4.44M
43.31%
-158.22K
2023Q2
299
4.48M
44.55%
-545.84K
2023Q1
319
4.85M
52.06%
-356.05K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Rubric Capital Management LP
2.95M
25.46%
+1.75M
+147.18%
Apr 18, 2025
Clearline Capital LP
635.22K
5.49%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
381.94K
3.3%
-5.64K
-1.46%
Mar 31, 2025
Tejara Capital Ltd.
344.60K
2.98%
-50.07K
-12.69%
Mar 31, 2025
Adar1 Capital Management LLC
270.16K
2.33%
--
--
Mar 31, 2025
Morgan Stanley & Co. LLC
130.12K
1.12%
-314.00
-0.24%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
116.13K
1%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
111.51K
0.96%
+3.17K
+2.93%
Mar 31, 2025
Walker (Marlan D)
73.64K
0.64%
+2.79K
+3.94%
Apr 18, 2025
Collins (Cooper C)
60.52K
0.52%
--
--
Apr 18, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
May 06, 2022
Merger
50<1
May 06, 2022
Merger
50<1
May 06, 2022
Merger
50<1
May 06, 2022
Merger
50<1
Fecha
Tipo
Relación
May 06, 2022
Merger
50<1
May 06, 2022
Merger
50<1
May 06, 2022
Merger
50<1
May 06, 2022
Merger
50<1
